GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nova Mentis Life Science Corp (OTCPK:NMLSF) » Definitions » Net Income

Nova Mentis Life Science (Nova Mentis Life Science) Net Income : $-0.24 Mil (TTM As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Nova Mentis Life Science Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Nova Mentis Life Science's Net Income for the three months ended in Mar. 2024 was $-0.11 Mil. Its Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.24 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Nova Mentis Life Science's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.00.


Nova Mentis Life Science Net Income Historical Data

The historical data trend for Nova Mentis Life Science's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nova Mentis Life Science Net Income Chart

Nova Mentis Life Science Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.66 -1.06 -19.70 -2.10 -1.82

Nova Mentis Life Science Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Mar24
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.30 -0.79 -0.39 -0.14 -0.11

Nova Mentis Life Science Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Nova Mentis Life Science's Net Income for the fiscal year that ended in Dec. 2022 is calculated as

Net Income(A: Dec. 2022 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-1.815+0+0+0
=-1.82

Nova Mentis Life Science's Net Income for the quarter that ended in Mar. 2024 is calculated as

Net Income(Q: Mar. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-0.106+0+0+0
=-0.11

Net Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nova Mentis Life Science  (OTCPK:NMLSF) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Nova Mentis Life Science's Earnings per Share (Diluted) (EPS) for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Nova Mentis Life Science Net Income Related Terms

Thank you for viewing the detailed overview of Nova Mentis Life Science's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Nova Mentis Life Science (Nova Mentis Life Science) Business Description

Traded in Other Exchanges
Address
700-838 West Hastings Street, Vancouver, BC, CAN, V6C 0A6
Nova Mentis Life Science Corp is a Canadian-based biotechnology company. It is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova uses psilocybin in the treatment of Fragile X Syndrome (FXS). The company's goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs such as autism spectrum disorder (ASD) and FXS. It has one industry segment, being research and development of psilocybin, and in one geographic area, which is Canada.

Nova Mentis Life Science (Nova Mentis Life Science) Headlines

From GuruFocus

Nova Mentis Announces Closing of Non-Brokered Financing

By PRNewswire PRNewswire 03-15-2022

Nova Mentis Files Genetic Neuroinflammatory Disease Patent

By PRNewswire PRNewswire 11-09-2021

U.S. FDA Approves Nova Mentis Orphan Drug Application

By PRNewswire PRNewswire 11-02-2021